Nasal  	Nasal  	 JJ	O
allergies  	allergies  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
Asian-Pacific  	Asian-Pacific  	 JJ	B-NP
population 	population 	 NN	I-NP
:  	:  	 :	O
results  	results  	 NNS	O
from  	from  	 IN	O
the  	the  	 DT	O
Allergies  	Allergies  	 NNP	O
in  	in  	 IN	O
Asia-Pacific  	Asia-Pacific  	 NNP	B-NP
Survey  	Survey  	 NNP	I-NP
The  	The  	 NNP	O
Allergies  	Allergies  	 NNP	O
in  	in  	 IN	O
Asia-Pacific  	Asia-Pacific  	 NNP	B-NP
Survey  	Survey  	 NNP	I-NP
describes  	describes  	 VBZ	O
the  	the  	 DT	O
symptoms 	symptoms 	 NNS	B-NP
,  	,  	 ,	O
impact 	impact 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
allergic  	allergic  	 JJ	B-NP
rhinitis  	rhinitis  	 NNS	I-NP
( 	( 	 -LRB-	O
AR 	AR 	 NNP	B-NP
)  	)  	 -RRB-	O
across  	across  	 IN	O
Australia 	Australia 	 NNP	B-NP
,  	,  	 ,	O
China 	China 	 NNP	O
,  	,  	 ,	O
Hong  	Hong  	 NNP	O
Kong 	Kong 	 NNP	O
,  	,  	 ,	O
Malaysia 	Malaysia 	 NNP	B-NP
,  	,  	 ,	O
Singapore 	Singapore 	 NNP	B-NP
,  	,  	 ,	O
Taiwan 	Taiwan 	 NNP	B-NP
,  	,  	 ,	O
Vietnam 	Vietnam 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
Philippines 	Philippines 	 NNPS	B-NP
.  	.  	 .	O
The  	The  	 DT	O
Allergies  	Allergies  	 NNP	O
in  	in  	 IN	O
Asia-Pacific  	Asia-Pacific  	 NNP	B-NP
Survey  	Survey  	 NNP	I-NP
was  	was  	 VBD	O
undertaken  	undertaken  	 VBN	O
to  	to  	 TO	O
further  	further  	 RB	O
clarify  	clarify  	 VB	O
the  	the  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
physician-diagnosed  	physician-diagnosed  	 JJ	O
nasal  	nasal  	 JJ	B-NP
allergies  	allergies  	 NNS	I-NP
( 	( 	 -LRB-	O
NAs 	NAs 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
impact  	impact  	 NN	O
on  	on  	 IN	O
quality-of-life  	quality-of-life  	 NNP	B-NP
( 	( 	 -LRB-	O
QOL 	QOL 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
existing  	existing  	 VBG	B-NP
treatment  	treatment  	 NN	I-NP
paradigms  	paradigms  	 NNS	I-NP
and  	and  	 CC	O
gaps 	gaps 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
NA  	NA  	 NNP	B-NP
medications  	medications  	 VBD	I-NP
currently  	currently  	 RB	O
used  	used  	 VBN	O
in  	in  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
Thirty-three  	Thirty-three  	 JJ	O
thousand  	thousand  	 CD	O
three  	three  	 CD	O
hundred  	hundred  	 CD	O
seventy-eight  	seventy-eight  	 JJ	O
households  	households  	 NNS	O
were  	were  	 VBD	O
screened  	screened  	 VBN	O
for  	for  	 IN	O
individuals 	individuals 	 NNS	O
,  	,  	 ,	O
≥  	≥  	 CD	O
4  	4  	 CD	O
years  	years  	 NNS	O
old 	old 	 JJ	O
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
physician  	physician  	 NN	B-NP
diagnosis  	diagnosis  	 NN	I-NP
of  	of  	 IN	I-NP
AR  	AR  	 NNP	I-NP
or  	or  	 CC	O
NA  	NA  	 NNP	B-NP
and  	and  	 CC	O
either  	either  	 DT	O
symptoms  	symptoms  	 NNS	B-NP
or  	or  	 CC	O
treatment  	treatment  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
past  	past  	 JJ	O
12  	12  	 CD	O
months 	months 	 NNS	O
.  	.  	 .	O
Standardized  	Standardized  	 JJ	O
questionnaires  	questionnaires  	 NN	O
were  	were  	 VBD	O
used  	used  	 VBN	O
to  	to  	 TO	O
make  	make  	 VB	O
comparisons  	comparisons  	 NNS	O
across  	across  	 IN	O
regions 	regions 	 NNS	O
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
1043  	1043  	 CD	O
adults  	adults  	 NNS	O
and  	and  	 CC	O
192  	192  	 CD	O
children  	children  	 NNS	O
were  	were  	 VBD	O
included  	included  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
survey 	survey 	 NN	O
.  	.  	 .	O
Nine  	Nine  	 CD	O
percent  	percent  	 NN	O
of  	of  	 IN	O
participants  	participants  	 NNS	B-NP
were  	were  	 VBD	O
diagnosed  	diagnosed  	 VBN	O
with  	with  	 IN	O
AR  	AR  	 NNP	B-NP
with  	with  	 IN	O
two  	two  	 CD	O
of  	of  	 IN	O
three  	three  	 CD	O
responding  	responding  	 NN	O
that  	that  	 IN	O
their  	their  	 PRP$	O
NAs  	NAs  	 NN	B-NP
were  	were  	 VBD	O
seasonal  	seasonal  	 JJ	O
in  	in  	 IN	O
nature 	nature 	 NN	O
.  	.  	 .	O
Nasal  	Nasal  	 JJ	B-NP
congestion  	congestion  	 NN	I-NP
was  	was  	 VBD	O
the  	the  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
and  	and  	 CC	O
bothersome  	bothersome  	 JJ	O
symptom  	symptom  	 NN	B-NP
of  	of  	 IN	I-NP
AR 	AR 	 NNP	I-NP
.  	.  	 .	O
Most  	Most  	 JJS	B-NP
participants  	participants  	 NNS	I-NP
reported  	reported  	 VBD	O
that  	that  	 IN	O
AR  	AR  	 NNP	B-NP
impacted  	impacted  	 VBD	O
their  	their  	 PRP$	O
QOL  	QOL  	 NN	B-NP
with  	with  	 IN	O
nearly  	nearly  	 RB	O
one-half  	one-half  	 JJ	B-NP
citing  	citing  	 VBG	I-NP
impairments  	impairments  	 NN	I-NP
in  	in  	 IN	O
school 	school 	 NN	B-NP
/ 	/ 	 CD	I-NP
work  	work  	 NN	I-NP
performance 	performance 	 NN	I-NP
/ 	/ 	 CD	I-NP
productivity 	productivity 	 NN	I-NP
.  	.  	 .	O
Sleep  	Sleep  	 JJ	B-NP
disturbances 	disturbances 	 NNS	I-NP
,  	,  	 ,	O
secondary  	secondary  	 JJ	O
to  	to  	 TO	O
AR 	AR 	 NNP	B-NP
,  	,  	 ,	O
were  	were  	 VBD	O
also  	also  	 RB	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
appreciable 	appreciable 	 JJ	O
.  	.  	 .	O
Two-thirds  	Two-thirds  	 NNS	B-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
took  	took  	 VBD	O
medication  	medication  	 NN	O
for  	for  	 IN	O
their  	their  	 PRP$	O
AR 	AR 	 NNP	B-NP
.  	.  	 .	O
Less  	Less  	 RBR	O
than  	than  	 IN	O
one-quarter  	one-quarter  	 NN	B-NP
of  	of  	 IN	I-NP
survey  	survey  	 NN	I-NP
respondents  	respondents  	 NNS	I-NP
reported  	reported  	 VBD	O
taking  	taking  	 VBG	O
an  	an  	 DT	O
intranasal  	intranasal  	 JJ	B-NP
corticosteroid  	corticosteroid  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
satisfaction  	satisfaction  	 NN	B-NP
rate  	rate  	 NN	I-NP
was  	was  	 VBD	O
similar  	similar  	 JJ	O
to  	to  	 TO	O
that  	that  	 DT	O
of  	of  	 IN	O
over-the-counter  	over-the-counter  	 JJ	B-NP
medications 	medications 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
most  	most  	 RBS	O
common  	common  	 JJ	O
reasons  	reasons  	 NNS	O
cited  	cited  	 VBD	O
for  	for  	 IN	O
dissatisfaction  	dissatisfaction  	 NN	B-NP
were  	were  	 VBD	O
related  	related  	 VBN	O
to  	to  	 TO	O
inadequate  	inadequate  	 JJ	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
bothersome  	bothersome  	 JJ	O
side  	side  	 NN	B-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
AR  	AR  	 NNP	B-NP
appears  	appears  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
extremely  	extremely  	 RB	O
common  	common  	 JJ	O
across  	across  	 IN	O
Asia-Pacific  	Asia-Pacific  	 JJ	B-NP
nations 	nations 	 NNS	I-NP
.  	.  	 .	O
Many  	Many  	 JJ	O
individuals  	individuals  	 NNS	O
with  	with  	 IN	O
AR  	AR  	 NNP	B-NP
suffer  	suffer  	 VBP	O
from  	from  	 IN	O
symptoms  	symptoms  	 NNS	B-NP
that  	that  	 WDT	O
reduce  	reduce  	 VBP	O
QOL  	QOL  	 NNP	B-NP
and  	and  	 CC	O
treatment  	treatment  	 NN	B-NP
gaps  	gaps  	 NNS	I-NP
exist  	exist  	 VBP	O
with  	with  	 IN	O
current  	current  	 JJ	O
therapies 	therapies 	 NNS	O
.  	.  	 .	O
Through  	Through  	 IN	O
identification  	identification  	 NN	B-NP
of  	of  	 IN	I-NP
disease  	disease  	 NN	I-NP
impact  	impact  	 NN	I-NP
and  	and  	 CC	O
highlighting  	highlighting  	 JJ	O
treatment  	treatment  	 NN	B-NP
gaps 	gaps 	 NN	I-NP
,  	,  	 ,	O
clinicians  	clinicians  	 NNS	B-NP
may  	may  	 MD	O
better  	better  	 RB	O
understand  	understand  	 VB	O
and  	and  	 CC	O
treat  	treat  	 VB	O
AR 	AR 	 NNP	B-NP
,  	,  	 ,	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
improvements  	improvements  	 NNS	B-NP
in  	in  	 IN	O
overall  	overall  	 JJ	O
patient  	patient  	 NN	O
satisfaction  	satisfaction  	 NN	O
and  	and  	 CC	O
QOL 	QOL 	 NNP	B-NP
.  	.  	 .	O
